A Retrospective Analysis of Brentuximab Vedotin and Pembrolizumab Combination As Salvage Treatment for Patients with Relapsed or Refractory Hodgkin Lymphoma

被引：0
|
作者：
Massaro, Fulvio
Meuleman, Nathalie
Bron, Dominique
Maerevoet, Marie
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-137399
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A Retrospective Analysis of Brentuximab Vedotin and Pembrolizumab Combination as Salvage Treatment for Patients with Relapsed or Refractory Hodgkin Lymphoma
    Massaro, Fulvio
    Maerevoet, Marie
    Meuleman, Nathalie
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S250 - S250
  • [2] Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis
    Massaro, Fulvio
    Meuleman, Nathalie
    Bron, Dominique
    Vercruyssen, Marie
    Maerevoet, Marie
    CANCERS, 2022, 14 (04)
  • [3] Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan
    Tien, Feng-Ming
    Tsai, Cheng-Hong
    Liu, Jia-Hau
    Lin, Chien-Ting
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2019, 118 (10) : 1466 - 1470
  • [4] Combination of Brentuximab Vedotin and Pembrolizumab as Salvage Treatment Before Autologous Stem Cell Transplantation and Maintenance in Patients with Relapsed/Refractory Hodgkin Lymphoma
    Massa, Hanne
    Massaro, Fulvio
    Maerevoet, Marie
    BIOMEDICINES, 2025, 13 (02)
  • [5] SALVAGE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA WITH BRENTUXIMAB VEDOTIN: THE GREEK EXPERIENCE
    Tsirigotis, P.
    Vassilakopoulos, T.
    Bousiou, Z.
    Mpatsis, I.
    Gkirkas, K.
    Sakellari, I.
    Papageorgiou, S.
    Roussou, P.
    Pangalis, G.
    Galani, Z.
    Moschoyianni, M.
    Vassilopoulos, G.
    Repoussis, P.
    Megalakaki, E.
    Michalis, E.
    Anagnostopoulos, N.
    Calpadaki, C.
    Papadaki, H.
    Margaritis, D.
    Chatzimichail, E.
    Briassoulis, E.
    Spyridonidis, A.
    Grentzelias, D.
    Anargyrou, K.
    Tsionos, K.
    Mpanti, A.
    Poulakidas, E.
    Palaska, C.
    Gribabi, D.
    Apostolidis, J.
    Pappa, V.
    Harhalakis, N.
    Panayiotidis, P.
    Konstantopoulos, K.
    Anagnostopoulos, A.
    Angelopoulou, M.
    HAEMATOLOGICA, 2015, 100 : 454 - 455
  • [6] Brentuximab vedotin treatment in patients with relapsed or refractory Hodgkin lymphoma
    Zsuzsa, Molnar
    Imre, Pinczes Laszlo
    Klara, Piukovics
    Ildiko, Istenes
    Krisztina, Wolf
    Zoltan, Csukly
    Arpad, Szomor
    Arpad, Illes
    Zsofia, Miltenyi
    ORVOSI HETILAP, 2017, 158 (41) : 1630 - 1634
  • [7] Is there a place for the combination of brentuximab vedotin and bendamustine in treatment of patients with relapsed/refractory Hodgkin lymphoma?
    Chen, Robert W.
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (11)
  • [8] BRENTUXIMAB VEDOTIN PLUS BENDAMUSTINE AS A SALVAGE TREATMENT REGIMEN FOR PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA
    LaCasce, A.
    Bociek, G.
    Sawas, A.
    Caimi, P.
    Agura, E.
    Matous, J.
    Ansell, S.
    Crosswell, H.
    Islas-Ohlmayer, M.
    Behler, C.
    Cheung, E.
    Forero-Torres, A.
    Vose, J.
    O'Connor, O. A.
    Josephson, N.
    Advani, R.
    HAEMATOLOGICA, 2016, 101 : 45 - 46
  • [9] Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma
    Forlenza, Christopher J.
    Gulati, Nitya
    Mauguen, Audrey
    Absalon, Michael J.
    Castellino, Sharon M.
    Franklin, Anna
    Keller, Frank G.
    Shukla, Neerav
    BLOOD ADVANCES, 2021, 5 (24) : 5519 - 5524
  • [10] Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients
    Ulu, Bahar Uncu
    Dal, Mehmet Sinan
    Hindilerden, Ipek Yonal
    Akay, Olga Meltem
    Mehtap, Ozgur
    Buyukkurt, Nurhilal
    Hindilerden, Fehmi
    Gunes, Ahmet Kursad
    Yigenoglu, Tugce Nur
    Basci, Semih
    Cakar, Merih Kizil
    Acik, Didar Yanardag
    Korkmaz, Serdal
    Ulas, Turgay
    Ozet, Gulsum
    Ferhanoglu, Burhan
    Nalcaci, Meliha
    Altuntas, Fevzi
    JOURNAL OF CHEMOTHERAPY, 2022, 34 (03) : 190 - 198
12345